Home » 2019 » February
Bexion Pharmaceuticals launches phase 1 part 3 trial of cancer drug BXQ-350

Bexion Pharmaceuticals launches phase 1 part 3 trial of cancer drug BXQ-350

US pharma company Bexion Pharmaceuticals has launched part 3 of their phase 1 human trial for BXQ-350 for cancer treatment. The early stage trial is aimed at determining the maximum tolerated dose of BXQ-350 and to characterize the safety and pharmacokinetics of the investigational cancer drug. The part 1 of the phase 1 trial saw […]

Alexion bags FDA priority review for SOLIRIS for treatment of NMOSD

Alexion Pharmaceuticals has bagged FDA priority review for the use of its C5 complement inhibitor SOLIRIS (eculizumab) as a treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients having anti-aquaporin-4 (AQP4) auto antibodies. The US pharma company’s supplemental Biologics License Application (sBLA), which has been accepted by the FDA, is backed by data from the […]

Continue reading …
Biohaven secures FDA orphan drug designation for MSA drug verdiperstat

Connecticut-based biopharma company Biohaven Pharmaceutical has secured orphan drug designation from the US FDA for its myeloperoxidase (MPO) inhibitor verdiperstat for the treatment of multiple system atrophy (MSA). According to Biohaven Pharmaceutical, verdiperstat (formerly known as BHV-3241) is an oral, brain-penetrant, irreversible inhibitor of the MPO enzyme. MPO is a key driver of pathological oxidative […]

Continue reading …
Chinese pharma companies to evaluate combo therapy in colorectal cancer

Chinese pharma companies Innovent Biologics and Shenzhen Chipscreen Biosciences have agreed to evaluate their respective drugs as combination therapy in advanced colorectal cancer. As per the agreement, Innovent’s Tyvyt (sintilimab injection) and IBI305 – a proposed biosimilar of Roche’s cancer drug bevacizumab will be evaluated in combination with Chipscreen Biosciences’ Chidamide. Tyvyt is a fully […]

Continue reading …
Orphan Technologies begins OT-58 phase 1/2 trial in classical homocystinuria

OT-58 clinical trial news : Swiss pharma company Orphan Technologies has dosed the first patients in a phase 1/2 trial, called CBS-HCY-01, of its modified recombinant enzyme therapy OT-58 in classical homocystinuria. OT-58 has been designed to dramatically reduce tissue and plasma levels of homocysteine, thereby potentially preventing, delaying, and reversing clinical abnormalities, and lifting […]

Continue reading …
Merck’s EMD Serono to expand biopharma R&D facility with $70m investment

German pharma company Merck will invest $70 million for the expansion of its US and Canada biopharma business EMD Serono’s research and development (R&D) facility in Billerica, Massachusetts. The expansion of the R&D facility through the addition of a new building is expected to enable drug discoveries in the areas of oncology, immuno-oncology and immunology. […]

Continue reading …
Fresenius Kabi launches Methocarbamol Injection, USP in US

German pharma company Fresenius Kabi has launched Methocarbamol Injection, USP in the US in a 100 mg per mL 10 mL vial presentation. Methocarbamol Injection, USP is to be used as a supplement to rest, physical therapy, and other measures to ease discomfort caused by acute, painful musculoskeletal conditions. It indicated for only intravenous and […]

Continue reading …
Novus Therapeutics begins phase 1 trial of OP0201 in otitis media

Clinical trial news : Novus Therapeutics has initiated a phase 1 pharmacodynamics clinical trial of its lead candidate OP0201 for the treatment of otitis media, an infection that affects the middle ear. The California-based specialty pharma company, which is focused on developing drugs for ENT disorders, has dosed the first adult patients in the early-stage […]

Continue reading …
Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma

ADCETRIS EC approval : The European Commission (EC) has expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to cover treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients. ADCETRIS is an antibody-drug conjugate (ADC) that targets CD30, which is a defining marker of […]

Continue reading …
Dr. Henry’s Vitamins introduces Prenatal Plus and Omega-3 for Women

Dr.Henry’s Vitamins has revealed their latest products, the Prenatal Plus and Omega-3 for Women, which are claimed to be made with the purest ingredients so that the body absorbs them all. Dr.Henry’s Vitamins was founded by Dr. Henry Dunklau, a doctor of pharmacy with a passion to inspire and educate people about vitamins, supplements, essential […]

Continue reading …
Page 1 of 212